Clinical Conundrums & Challenging Cases in the Bone Health of Transgender Individual

Includes a Live Web Event on 02/22/2025 at 10:45 AM (EST) Includes a Live In-Person Event on 02/22/2025 at 10:45 AM (EST)

Only available as part of a package

Transgender and gender diverse (TGD) people are at increased risk for bone loss due to changes in their hormonal milieu. The ISCD recommends screening for low bone density in TGD people especially in those who are at high risk for bone loss and/or may not reach peak bone mass. This case based session will discuss different clinical situations where bone density screening should be performed and when treatment should be considered.

OBJECTIVES
  1. Review ISCD guidelines for screening for low bone density in transgender and gender diverse people  
  2. List conditions that might put transgender and gender diverse people at increased risk for bone loss  
  3. Discuss potential treatment options for transgender and gender diverse people
LOCATION

Georgian room

Vin Tangpricha, MD, PhD

Professor of Medicine, Eminent Physician

Division of Endocrinology, Metabolism & Lipids, Emory University School of Medicine

Vin Tangpricha is a Professor of Medicine in the Division of Endocrinology, Metabolism and Lipids at Emory University School of Medicine in Atlanta, Georgia. Dr. Tangpricha received his medical degree from Tufts University School of Medicine and completed his internal medicine residency and endocrinology fellowship at Boston University Medical Center. He completed his PhD in molecular medicine on the topic of vitamin D at Boston University School of Medicine. He serves on the Endocrine Society guidelines committee for the hormone treatment of gender-non-conforming and gender incongruent patients, which has published two international guidelines on transgender patients (2009 and revised in 2017). He served on the World Professional Association for Transgender Health (WPATH) guidelines for the Standards of Care (SOC) for Transgender people as the endocrine section chair. He is the immediate past-president of WPATH. He has received funding from the Cystic Fibrosis Foundation and NIH. He has published over 250 peer reviewed manuscripts on transgender medicine, vitamin D, and cystic fibrosis.

This activity has been approved by ASRT for 1.5 Category A continuing education credits.

If you want to claim credits for ACCME you will be able to at the end of the conference at this link:
https://learn.iscd.org/product...

Components visible upon registration.
;